Condition: Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV) · Idiopathic Inflammatory Myositis (IIM) · Systemic Sclerosis (SSc) · Sponsor: Fate Therapeutics
This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate-to-severe active systemic lupus erythematosus (SLE) with or without nephritis, antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.
This description comes directly from the study's public registry record.
Fate Clinical Trials · 858-875-1800 · clinicaltrials@fatetherapeutics.com
Always discuss trial participation with your own doctor first.
| Wallace Rheumatic Center | Beverly Hills, California, United States | Recruiting |
| Providence Medical Foundation | Fullerton, California, United States | Recruiting |
| University of California Irvine | Irvine, California, United States | Recruiting |
| Children's Hospital Los Angeles Division Of Rheumatology | Los Angeles, California, United States | Recruiting |
| University of California San Francisco | San Francisco, California, United States | Recruiting |
| University of Florida | Gainesville, Florida, United States | Recruiting |
| Nicklaus Children's Hospital | Miami, Florida, United States | Recruiting |
| University of Louisville | Louisville, Kentucky, United States | Recruiting |
| University of Minnesota Medical School | Minneapolis, Minnesota, United States | Recruiting |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| Montefiore Medical Center | New York, New York, United States | Recruiting |
| Duke University Health System | Durham, North Carolina, United States | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06308978